84 at last check on Friday, Nov 20, making an upward move of 18. (NASDAQ: APRE) made its public debut Thursday morning, opening at . They issued a neutral rating on the stock. View the latest APRE stock quote and chart on MSN Money. holds several positive signals, but we still don&39;t find these to be enough for a buy candidate. Find the latest Aprea Therapeutics, Inc. In depth view into APRE (Aprea Therapeutics) stock including the latest price, news, dividend history, earnings information and financials.
Customizable interactive chart for Aprea Therapeutics Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. Aprea Therapeutics&39; stock opens 3. Analyst Actions: HC Wainwright Initiates Coverage on Aprea Therapeutics With Neutral Rating, Price Target 7:55AM ET MT Newswires.
View today&39;s stock price, news and analysis for Aprea Therapeutics Inc. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Aprea Therapeutics against related stocks people have also bought. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor. 1% above IPO price, then rises further MarketWatch. The Company had 21,186,827 shares of common stock outstanding as of Septem. Get Aprea Therapeutics Inc historical price data for APRE stock. 00 and the low price target for APRE is .
APRE, Aprea Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines. APRE detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. APRE investment & stock information. 46 after being priced at per share. 75%) Post-Market 0. 98 and the beta (5Y monthly) reads 0 with the day’s price range being .
Common stock (APRE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The high price target for APRE is . · Aprea Therapeutics. Aspiring to be the global leader in p53-targeted cancer therapies. 87, Percent Change: +5. · Aprea Therapeutics&39; stock opens 3. com has aprea therapeutics stock price all the historical stock data including the closing price, open, high, low, change and % change.
View daily, weekly or monthly format back to when Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. Aprea Therapeutics started at neutral with stock price aprea therapeutics stock price target at J. View which stocks have been most impacted by COVID-19. Aprea Therapeutics&39; (APRE) average rating among analysts is a hold, with an average price target of . Since then, APRE stock has decreased by 15. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer.
Aprea Therapeutics, Inc. Filter by: Real-Time. View the real-time APRE price chart on Robinhood and decide if you want to buy or sell commission-free. Stock Price Forecast for APRE: Aprea Therapeutics Inc. The Investor Relations website contains information about Aprea Therapeutics&39;s business for stockholders, potential investors, and financial analysts. Equal Weight Rating for Aprea Therapeutics by Morgan Stanley from 12/16/20. Looking at the stock we see that its previous close was . operates as a clinical-stage biopharmaceutical company.
Aprea Therapeutics, Inc. 1% above IPO price, then rises further. 1% above IPO price, then rises further Oct. Company profile page for Aprea Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information. 1% and is now trading at . View the latest Aprea Therapeutics Inc. 3, at 11:09 a. 00, predicting that the stock has a possible upside of 61.
37%) Wed,, 4:00PM EST Dive deeper with interactive charts and top stories of Aprea Therapeutics, Inc. Their average twelve-month price target is . Morgan MarketWatch. HC Wainwright restated a hold rating and set a . Finally, JPMorgan Chase & Co. Aprea Therapeutics&39; stock was trading at . See full list on finance.
About Aprea Therapeutics, Inc. Stock analysis for Aprea Therapeutics Inc (APRE:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company aprea profile. (NASDAQ:APRE) traded at . A high-level overview of Aprea Therapeutics, Inc.
, a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. 4% on its previous day’s price. The average 1-year price. Real time Aprea Therapeutics Inc (APRE) stock price quote, stock graph, news & analysis. Barron&39;s also provides information on historical stock ratings, target prices, company earnings, market valuation. initiated coverage on Aprea Therapeutics in a research report on Tuesday, September 29th.
Stock Price: APRE (NasdaqGS) . Quote Stock Analysis News Price aprea therapeutics stock price vs Fair Value Trailing Returns Financials. 00 price objective on shares of Aprea Therapeutics in a research report on Wednesday, August 12th. Get the latest Aprea Therapeutics, Inc. (APRE) stock quote, history, news and other vital information to help you with your stock trading and investing.
Thursday, Octo. 54%) PRIVATE Updated 12:31 AM. At the current level, it should. 5 Wall Street analysts have issued ratings and price targets for Aprea Therapeutics in the last 12 months. ET by Tomi Kilgore Aprea Therapeutics to offer 5 million shares in its IPO, priced at to . One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy aprea therapeutics stock price rating to the company. Find real-time APRE - Aprea Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.
54 on March 11th, when COVID-19 reached pandemic status according to the World Health Organization (WHO). stock was issued. · View Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate. Aprea Therapeutics (NASDAQ:APRE) has been given a consensus rating of “Hold” by the eight analysts that are presently covering the company, MarketBeat Ratings reports. Corporate Profile. Discover historical prices for APRE stock on Yahoo Finance.
Monday, Septem. Aprea Therapeutics, Inc. APRE - Aprea Therapeutics Inc Stock quote - CNNMoney. APRE: Get the latest Aprea Therapeutics stock price and detailed information including APRE news, historical charts and realtime prices. Aprea Therapeutics to offer 5 million shares in its IPO, priced at to each. Common stock (APRE) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Market Watch - 1 year ago Aprea Therapeutics&39; stock opens 3. · aprea therapeutics stock price Aprea Therapeutics, Inc.
(APRE) stock price, news, historical charts, analyst ratings and financial information from WSJ. Get full conversations at Yahoo Finance.
-> How much is cvs stock
-> Top european growth stocks